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Summary Cisplatin (CDDP) resistance mechanisms were studied in a model of three germ cell tumour and
three colon carcinoma cell lines representing intrinsically CDDP-sensitive and -resistant tumours respectively.
The CDDP sensitivity of the cell lines mimicked the clinical situation. The glutathione levels of the cell lines
correlated with CDDP concentrations inhibiting cell survival by 50% (IC5o); total cellular sulphydryl content
(TSH) was unexpectedly inversely correlated with ICu. ICs correlated neither with glutathione S-transferase
(GST) nor with GSTx expression, topoisomerase I or II activity. Immediately after 4 h incubation with
CDDP, platinum (Pt) accumulation and Pt bound to DNA were not correlated, but after another 24h
drug-free culture, Pt binding to DNA in germ cell tumour but not in colon carcinoma cell lines correlated with
ICn. With the exception of in vitro sensitivity and TSH, none of the parameters studied discriminated between
the two groups of cell lines. Correction of CDDP sensitivity parameters for phenotypical differences did not
influence statistical correlations. Analysis of variance revealed a correlation between IC50 and the combination
ofglutathione, GST activity and Pt bound to DNA. But at other CDDP cytotoxicity levels sensitivity was also
correlated with Pt accumulation, topoisomerase II activity and TSH in various combinations. This model of
intrinsic CDDP resistance showed that multiple parameters ought to be studied to explain CDDP resistance,
but did not elucidate the cause of the unique sensitivity of germ cell carcinoma, although the unexpected
values of TSH deserve further attention.
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The antineoplastic drug cis-diamminedichloroplatinum(II)
(cisplatin, CDDP) is an extremely active drug in the treat-
ment of patients with disseminated testicular germ cell
tumours. Over 80% of these patients can be cured with a
CDDP-containing drug regimen (Loehrer and Einhorn,
1984). In contrast, no cures can be obtained with this com-
pound in patients with colon cancer and most other solid
tumours (Loehrer and Einhorn, 1984). Understanding of
CDDP sensitivity and resistance has predominantly come
from the stsudy of cell lines selected for CDDP resistance by
in vitro drug incubations (for review see Andrews and
Howell, 1990). These studies revealed several causes for
CDDP resistance. Relevant mechanisms are decreased cel-
lular accumulation of CDDP, increased detoxification, by
either the glutathione (GSH) or the metallothionein system,
and enhanced DNA repair, often resulting in decreased DNA
platination (for review see Andrews and Howell, 1990). In
most cases of in vitro acquired CDDP resistance, a combina-
tion of these factors is found. Unselected cell lines may
provide a cellular model of drug resistance that is more
representative of the clinical situation. Bedford et al. (1988)
previously used germ cell and bladder tumour cell lines as the
CDDP-sensitive and -resistant representatives of a model. In
that study, a correlation of CDDP sensitivity with platinum
(Pt) accumulation and deficient DNA damage repair in one
of the two germ cell cell lines was found. In general, for germ
cell tumour cell lines a greater sensitivity to CDDP has been
reported compared with cell lines derived from other solid
tumour types (Oosterhuis et al., 1984; Pera et al., 1987;
Walker et al., 1987; Bedford et al., 1988; Parris et al., 1990;
Kelland et al., 1992; Masters et al., 1993; Hill et al., 1994).
In the present study parameters potentially relevant to
CDDP sensitivity were examined in three germ cell tumour
and three colon carcinoma cell lines, as their original
tumours reflect extremely sensitive and resistant tumour
types. Cellular detoxification mechanisms, Pt accumulation,
DNA platination and repair and the nuclear enzymes DNA
topoisomerase (topo) I and II were compared as they may
contribute to cellular CDDP sensitivity. In order to achieve a
good definition of the model, basic cellular characteristics of
the cell lines were also determined.
Materials and methods
CDDP was obtained from Bristol-Myers (Weesp, The
Netherlands) and RPMI-1640 medium, Leibovitz L15
medium and fetal calf serum (FCS) from Life Technologies
(Paisley, UK). GSH, 3-(4,5-dimethylthiazol-2yl)-2,5-diphenyl-
tetrazolium, sodium pyruvate, protease XXIV and propidium
iodide were purchased from Sigma (St Louis, MO, USA).
5-Bromo-2'-deoxyuridine was obtained from Serva (Heidel-
berg, Germany), rabbit anti-mouse immunoglobulin [F(ab)2
fragments, fluorescein conjugated] from Dakopatts (Glos-
trup, Denmark), glutamine from Flow Laboratories (Irvine,
UK) and diaminobenzoic acid from Fluka (Buchs, Ger-
many). Nuclease P1 and DNAse I were purchased from
Boehringer Mannheim (Almere, The Netherlands).
For the cell lines used in this study, origin and pretreat-
ment were as described in Table I. The subclone NTera2/D1
(Tera; Timmer-Bosscha et al., 1993) of Tera-2 (Fogh, 1978),
833 KE (Bronson et al., 1980) and Scha (Andrews et al.,
1987) were used as germ cell tumour cell lines and Colo 320
(Quin et al., 1979), SW 948 (Leibovitz et al., 1976), and
Caco-2 (Fogh et al., 1977) as colon carcinoma cell lines. All
cell lines, except SW 948, were cultured in RPMI-1640 with
10% heat-inactivated (30 min, 56°C) FCS. SW 948 was cul-
tured in Leibovitz L15-RPMI-1640 (1:1) enriched with
12.5% FCS, 0.05 M pyruvate, 0.1 M glutamine and 0.025%
(v/v) P-mercaptoethanol. Tera, 833 KE, SW 948 and Caco-2
were grown as monolayers, Colo 320 grew loosely attached
and Scha grew attached and partly in suspension. Firmly
attached cells were harvested by scraping or treatment of
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Table I Origin and previous treatment of the three germ cell tumour and the three colon carcinoma cell lines
Cell line Tumour oforigin Site Previous treatment Reference
Tera-2, clone Ntera2/Dl Embryonal carcinoma Lung metastasis Radio- and Fogh (1978)
chemotherapy (no CDDP)
833 KE Embryonal carcinoma, Abdominal metastasis Chemotherapy (no CDDP) Bronson et al. (1980)
teratoma,
choriocarcinoma, seminoma
Scha Embryonal carcinoma, Bone metastasis Radiotherapy Andrews et al. (1987)
seminoma
Colo 320 Adenocarcinoma Colon No radio- or chemotherapy Quin et al. (1979)
SW 948 Adenocarcinoma Colon No radio- or chemotherapy Leibovitz et al. (1976)
Caco-2 Adenocarcinoma Colon No radio- or chemotherapy Fogh et al. (1977)
cultures with protease XXIV for 10 min. Scha and Colo 320
were harvested by gentle shaking. All cell lines were cultured
at 37°C in a humidifed atmosphere with 5% carbon dioxide.
CDDP sensitivity was analysed with the microculture tetra-
zolium assay as described previously (Timmer-Bosscha et al.,
1989). Before the assays were performed, the linear relation-
ship of cell number to formazan crystal formation was
checked and cell growth studies were performed. Each cell
line was seeded at optimum density in order to test survival
after at least two or three cell divisions had taken place in the
control cells. This was day 4 for Tera, 833 KE, Scha and
Colo 320 and day 6 for SW 948 and Caco-2. For Tera, 833
KE and Scha 1 x 104, 1.5 x 104 and 3 x 104 cells, respec-
tively, were incubated continuously with a range of CDDP
concentrations, in a total volume of0.2 ml ofculture medium
in 96-well plates. For Colo 320, SW 948 and Caco-2,
2.5 x 103, 5 X 103 and 1 x I04 cells, respectively were
incubated continuously in a total volume of 0.1 ml. A
minimum of three experiments per cell line was performed,
each in quadruplicate.
Population doubling time during log phase was determined
by cell count in a haemocytometer with trypan blue dye
exclusion as a measure of viability. Experiments were
repeated three times for each cell line. Cell cycle distribution
was determined according to Preisler et al. (1992). In brief,
exponentially growing cells were incubated with 10 LM 5-
bromo 2'-deoxyuridine for 30 min, washed with phosphate-
buffered saline (PBS; 0°C) and fixed in 70% ethanol (0°C).
Cells were resuspended in hydrochloric acid of a molarity
that gave optimal results (Tera, 833 KE, Scha and Colo 320,
all 2.5 M; SW 948 and Caco-2, 3 M), subsequently incubated
with anti-5-bromo 2'-deoxyuridine monoclonal antibody, a
second antibody [rabbit anti-mouse/F(ab)2 fluorescein con-
jugated] and washed with PBS. Finally propidium iodide
20ligml-' was added and fluorescence was analysed on a
flow cytometer (FACS 440, Becton Dickinson, Sunnyvale,
CA, USA). Calculations and statistical analysis of cell cycle
distribution were performed with the analysis program Con-
sort 30 version. G12/88 (Becton Dickinson). Reported values
are the mean of three separate measurements. Relative cell
volume was determined on a flow cytometer (FACStar, Bec-
ton Dickinson, Sunnyvale, CA, USA) scanning the forward
scatter of unstained viable cells.
Cellular protein was determined according to Lowry et al.
(1951). For nuclear protein determination cell nuclei were
isolated as described by De Jong et al. (1990) and total
nuclear protein contents were determined according to Brad-
ford (1976). For both protein determinations three or more
separate experiments were performed for each cell line. DNA
content was measured in 0.5 x 106 cells by the diaminoben-
zoic acid assay (Kissane and Robins, 1958). In each assay a
standard curve with salmon sperm DNA in 1 M ammonium
hydroxide was included. A minimum of three separate
experiments for each cell line were performed.
The conditions and measurements for GSH, total sulph-
ydryl content (TSH) and glutathione S-transferase (GST)
activity in the cell lines were as described previously (Hospers
et al., 1988) Reported values are the mean of three indepen-
dent experiments. The amount of GST7 isoenzyme was
determined in all lines using sodium dodecyl sulphate-poly-
acrylamide gel electrophoresis followed by Western blotting
and subsequent incubation with a monoclonal antibody
raised against GSTic (Peters et al., 1989, 1992). For each line
the expression was determined in three independent cell pro-
tein extracts.
The topo I and II catalytic activities were determined in
0.35M sodium chloride nuclear extracts of cells in the
logarithmic phase of growth by relaxation of supercoiled
PBR 322 (topo I) and the decatenation assay (topo II), with
270, 90, 30, 10, 3, 1 and 0.3 ng of protein, as described
previously (De Jong et al., 1990). Experiments were per-
formed in triplicate, while the small-cell lung cancer cell line,
GLC4, was included as a reference (De Jong et al., 1990).
For determination of cellular Pt content, 5 x 106 cells of
each cell line were incubated for 4 h at 37°C with CDDP
concentrations ranging from 33 to 100 M. After washing
three times with PBS (0°C) pellets were dissolved in 0.5 ml
65% nitric acid in an oven at 70°C for 2 h. Thereafter the Pt
content was determined by atomic absorption spectro-
photometry (AAS) as described previously (Hospers et al.,
1988). At each CDDP concentration experiments were per-
formed in triplicate or quadruplicate. For measurements of
Pt bound to DNA a total of 5 x 107 cells ofeach cell line was
treated with CDDP concentrations ranging from 33 to
1I00 lM for 4 h at 37°C. Cells were washed three times with
PBS (0°C). DNA was isolated and the amounts of DNA and
Pt were measured as described previously (Hospers et al.,
1988). At each CDDP concentration experiments were per-
formed in quadruplicate. The kinetics of Pt bound to total
nuclear DNA were determined after a 4 h incubation of 108
cells with 16.5 LM CDDP in germ cell tumour cell lines. After
incubation with 16.5itM, Pt bound to DNA in the Tera cells
was at the detection limit of the AAS. A main drawback of
this dose was that it was 7-24 times the ICso of the germ cell
tumour cell lines. In order not to favour the colon carcinoma
cell lines in this respect, the colon carcinoma cell lines were
incubated with 33 .LM CDDP (4-8 times their ICW). Incuba-
tion of the colon carcinoma cell lines with a higher CDDP
concentration was avoided as it would lead to too high a
level of Pt binding to DNA and therefore would invalidate
the comparison. Immediately after incubation (t = 0) one
part of each sample was washed with PBS (0C, three times);
in the other part medium was refreshed and cells were kept
at 37°C for 24 h and then washed with PBS (t = 24) as
above. Both parts were further processed for measurement of
Pt bound to DNA. In order to decrease sample viscosity for
Pt and DNA measurements, DNA was digested by nuclease
P1 (7.8jig 10-6 cells) and DNAse I (8.4 U 10-6 cells) in a
buffer containing 10 mM Tris, 4 mM magnesium chloride,
0.1 mM EDTA and 0.24 mM zinc sulphate. Pt amount in
these samples was measured as described previously (Hospers
et al., 1988) with in addition Zeeman background correction.
The addition of this equipment to the AAS apparatus
allowed the differential correction of the background absorp-Cisplatin sensitivity in germ cell and colon cancercell lines
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tion over the temperature range used to atomise the Pt, this
in contrast to the fixed background value, established at one
temperature, obtained without the use of Zeeman correction.
Absolute values of Pt bound to DNA after 24 h were cor-
rected for DNA synthesis over this time course, by deter-
mination of the dilution of the specific activity of DNA of
cells incubated with [3H]thymidine before CDDP incubation
(Hospers et al., 1988). The dilution factor was calculated as:
specific activity at t = 24 divided by specific activity at t = 0.
Immediately after all CDDP incubations and at t = 24 in the
repair samples, cell viability was tested by trypan blue dye
exclusion.
Differences between the group of germ cell tumour and the
group of colon carcinoma cell lines were analysed with the
Student's t-test for unpaired samples. Correlation coefficients
were determined by Spearman rank analyses. Analyses of
variance were performed using the SPSS program for medical
statistics (SPSS, Chicago, MI, USA). Only P-values <0.05
were considered significant.
Results
The survival curves of the cell lines after continuous CDDP
incubation are shown in Figure 1. The CDDP concentrations
inhibiting survival by 50% (IC50) ranged from 0.69 to
7.90 jtM, thus a maximum 11.4-fold difference in sensitivity
between the cell lines was found. The germ cell tumour cell
lines are the most sensitive lines with IC50 values ranging
from 0.69 to 2.42 Lm, while the ICso values of the colon
carcinoma cell lines ranged from 4.16 to 7.90 SM. There was
a significant difference between the mean IC50 of the germ







Figure 1 Survival of Tera (0), 833 KE (0), Scha (A), Colo 320
(0), SW 948 (-) and Caco-2 (A) after continuous incubation
with CDDP measured by microculture tetrazolium assay. The
mean IC50 values of the group of germ cell tumour and colon
carcinoma cell lines were significantly different (P<0.01; n = 3).
In Table II the basic phenotypical parameters, namely cell
doubling time, relative cell volume, cellular protein, nuclear
protein, cellular DNA content and percentage of cells in
S-phase, are shown for all cell lines. For these characteristics
up to 4-fold differences were observed. Only relative cell
volume was significantly larger in the group of germ cell
tumour than in the group of colon carcinoma cell lines
(P<0.025). No correlations with CDDP sensitivity were
found as far as these basic cellular characteristics were con-
cerned.
Mean cellular GSH level (Table III) was not significantly
lower in the germ cell tumour than in the colon carcinoma
cell lines. But GSH levels of the six cell lines were positively
correlated with CDDP ICs (r = 0.90, P<0.05). Surprisingly,
TSH levels showed an inverse correlation with CDDP IC50
(r = -0.94, P<0.05). There was also a significant difference
between both groups of cell lines with respect to TSH
(P<0.025) (Table III). GST activity and the amount of
GSTx (Table III) were not significantly different between
both groups of tumours, nor was either parameter statis-
tically related to CDDP sensitivity. There was no relation
between GST activity and the amount of GSTsc in the cell
lines.
No difference was found between the topo I activities in
the nuclear protein extracts of all cell lines, and activities
were similar to the topo I activity of GLC4 (for GLC4 a
mean of 1 ± 1 ng nuclear protein was needed to observe
complete relaxation of plasmid DNA). When topo II activity
was expressed relative to GLC4 (for GLC4, with a mean of
10 ± 4 ng nuclear protein or less decatenation was no longer
observed), five of the cell lines had higher topo II activities.
The mean topo II activity was not different between the
group of germ cell tumour and the group of colon carcinoma
cell lines. Within the panel of cell lines tested, one germ cell
tumour cell line had a higher topo II (833 KE) and one colon
carcinoma cell line a lower topo II (Colo 320). There was no
correlation between topo II activity and the amount of
nuclear protein, DNA per cell or percentage of cells in
S-phase.
Cellular Pt content in the various cell lines is shown in
Figure 2. Immediately after 4 h incubation with CDDP no
loss ofcell viability was observed (data not shown). Neither a
difference in accumulation between both groups nor a rela-
tion with CDDP sensitivity was found. Correlation of cel-
lular Pt content for cellular protein or relative cell volume
did not reveal a more obvious statistical relation with CDDP
sensitivity. In the most sensitive germ cell tumour cell line,
Tera, a low cellular Pt level was found, while in Scha cellular
Pt levels were generally high compared with other cell lines.
Although in two of the three germ cell carcinoma cell lines a
relatively high amount of Pt bound to DNA was found (833
KE, Scha) neither a difference between the groups of tumour
cell lines nor a correlation with CDDP sensitivity was found
(Figure 3). Calculation of the amount of Pt bound to DNA
per 106 cells, thus correcting for the large differences in DNA
content per cell, did not improve the relation between Pt
bound to DNA and CDDP sensitivity. Measurement of Pt
bound to DNA 24 h after a 4 h CDDP incubation revealed
an increase, compared with t = 0, in one germ cell tumour
and one colon carcinoma cell line, no alteration over this
period in another cell line of both cell types and a decrease of
Pt bound to DNA in the third cell line of both cell types
Table II Cellular characteristics ofthe three germ cell tumour (Tera, 833 KE, Scha) and the three colon carcinoma (Colo 320, SW948,
Caco-2) cell lines expressed as indicated
Cellular protein Nuclear protein DNA content Percentage ofcells
Cell line Doubling time Relative cell volume0 (j.g 10-6 cells) (1sg 10-6 nuclei) (1tg 10-6 cells) in S-phase
Tera 14.0 0.6b 116.0 233 62 29.1 ±5.2 15.8 ± 4.5 46.7 2.2
833 KE 25.3 2.1 110.0 5.8 372 43 49.4 8.4 19.8 ± 3.1 55.1 2.9
Scha 35.6± 11.6 99.6±3.6 165 18 52.5± 16.1 15.7±0.8 24.6± 1.4
Colo 320 15.2 ± 0.6 84.2 ± 1.6 235 ± 12 26.9 ± 3.7 7.6 ± 0.8 42.7 ± 2.3
SW 948 19.0 ± 1.2 76.8 ± 2.4 356 ± 45 30.8 ± 7.4 25.7 ± 2.4 56.7 ± 3.2
Caco-2 30.3 11.4 91.0 1.2 330 30 95.6 10.2 31.8 ± 4.7 31.0 10.0
'Significant difference between the group of germ cell and the group of colon carcinomas (P<0.025). bMean ± s.d. (n > 3).
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Table III CDDP sensitivity-related parameters of the three germ cell tumour (TERA, 833 KE,
Scha) and the three colon carcinoma (Colo 320, SW 948, Caco-2) cell lines expressed per mg of
cellular protein
TSH GSH GST activity GST-i
(14g TSHa) (rig GSHb) (nmol CDNBc min') (ttg GST-i) Topo IId
Tera 65.7 l0.le 1.9±0.2 95±8 6.3± 1.8 3
833 KE 52.5 16.9 5.6 1.9 90 12 3.9 0.6 10
Scha 38.6 ±4.0 9.8 1.6 36 9 6.9 1.2 3
Colo 320 25.7 ± 8.3 7.7 ± 0.8 75 ± 40 4.2 ± 0.4 1
SW948 26.5±9.9 9.8±2.9 68±31 4.3±0.5 3
Caco-2 21.4 ± 6.0 12.3 ± 1.8 255 ± 25 7.2 ± 0.9 3
aSpearman rankanalysisofTSH vsICs, r=-0.94, P<0.05.bSpearman rankanalysis ofGSH vs
IC50, r = 0.90, P<0.05.cl-Chloro-2,4-dinitrobenzene. dTopoIIactivityrelative tothecelllineGLC4
(deJong etal., 1990). Topo II activityfor GLC4 was no longer seenwhen 10 ± 4 ngproteinperlane












Figure 2 Cellular Pt accumulation after 4 h CDDP incubation
determined with AAS of Tera (1), 833 KE (2), Scha (3), Colo 320
(4), SW 948 (5) and Caco-2 (6) (n = 3-4). Neither a significant
difference between both groups of cell lines nor a correlation of
Pt accumulation with CDDP sensitivity was found.
(Table IV). Values shown in Table IV are corrected for DNA
synthesis. DNA specific activity decreased; dilution factors
varied from 0.46 to 0.74 in the six cell lines and were not
different between the group of germ cell tumour and the
group of colon carcinoma cell lines. Although within the
group of germ cell tumour cell lines a good correlation
between Pt bound to DNA at t= 24 and IC50 was found, no
correlation was found within the group of colon carcinoma
cell lines.
Statistical processing of data by analysis of variance was
performed to detect whether it was possible to relate com-
binations of parameters to sensitivity. The sensitivity of the
cell lines, defined as CDDP IC50, was correlated with GSH in
combination with Pt bound to DNA (100 gAM CDDP incuba-
tion) and GST activity (r = 0.997, P = 0.010). Any other
combination of parameters did not reveal significant correla-
tions with IC50. However, even for a combination of
parameters, no difference between the group of germ cell
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Figure 3 Amount of Pt bound to DNA after 4 h CDDP incuba-
tion determined with AAS of Tera (1), 833 KE (2), Scha (3),
Colo 320 (4), SW 948 (5) and Caco-2 (6) (n = 4). Neither a
significant difference between both groups of cell lines nor a
correlation of Pt bound to DNA with CDDP sensitivity was
found.
found at the ICm level. Analyses of variance were also per-
formed in relation to a level of a CDDP concentration
inhibiting survival by 10% (IC1o) and a concentration
inhibiting survival by 90% (IC90). ICIo correlated with GSH
combined with cellular Pt accumulation (67 JAM CDDP
incubation) and topo II activity (r = 0.994, P = 0.018). When
IC1o was related to the combination of GSH/Pt accumulation
there was also a significant difference between both groups of
cell lines. When ICgO values were correlated with Pt bound to
DNA (100;AM CDDP incubation) and TSH, a difference
between the groups of cell lines was found as well as correla-
tion with sensitivity at this high cytotoxicity level.
Discussion
In this study the survival curves of the cell lines after CDDP
incubation show that the model with germ cell tumour and
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Table IV Values of Pt bound to DNA immediately (t = 0) and 24 h
(t = 24) after a 4 h incubation with 16.5lM CDDP for the three germ
cell tumour (Tera, 833 KE, Scha) and 33 LM for the three colon
carcinoma (Colo 320, SW 948, Caco-2) cell lines
Pt bound to DNA, Pt bound to DNA,
t=Oh t=24h
(ng mg 'DNA) (ngmg' DNA)
Tera 28.2 19.7a 61.3 43.3
833 KE 32.1 ± 6.5 35.2 ± 23.3
Scha 26.9 4.2 16.6 3.2
Colo 320 48.4 + 10.2 32.2 ± 15.7
SW 948 46.3 12.8 61.7 26.0
Caco-2 48.7 3.3 44.0 8.1
aMean ± s.d. (n = 3-4).
sensitive and -resistant tumours mimics the clinical situation.
The advantage of this model is that it allows the analysis of
parameters of possible relevance to CDDP sensitivity in
intrinsically resistant cells, in which different mechanisms
may be operational than those activated in acquired resis-
tance. Analogous models have been described previously
(Bedford et al., 1988; Fry et al., 1991; McLaughlin et al.,
1993). Germ cell tumour cell lines (sensitive) have been com-
pared with bladder carcinoma cell lines (resistant) with
respect to topo II levels and sensitivity to drugs that exert
activity via topo II (Fry et al., 1991). Also, the correlation of
CDDP sensitivity with the capacity to repair specific
Pt-DNA adducts of germ cell and bladder tumour cell lines
has been described (Bedford et al., 1988). In another study
the binding activities of cisplatin damage recognition proteins
in germ cell and bladder tumour cell lines were compared
(McLaughlin et al., 1993). In the present study the basic
characteristics of the cell lines and multiple mechanisms
previously described to be of importance in in vitro acquired
resistance were evaluated including topo II activity and the
kinetics of Pt bound to DNA. Basic characteristics varied
widely among the six cell lines. But correction of resistance-
related parameters for differences in basic characteristics that
were thought to affect the estimation of a certain resistance
mechanism did not influence statistical correlations.
Increased GSH is generally considered a relevant mecha-
nism in CDDP resistance (Hosking et al., 1990; Meijer et al.,
1990; Mistry et al., 1991). It has been described to play a role
in germ cell tumour (Meijer et al., 1992; Timmer-Bosscha et
al., 1993) as well as in colon carcinoma cell lines (Fram et al.,
1990) with acquired CDDP resistance. In our panel of cell
lines cellular GSH content showed a positive correlation with
IC50. This correlation with a median cytotoxicity level
differed from the results obtained by Peters et al. (1991).
They found that GSH protection was most effective at
CDDP concentrations inducing over 90% kill when they
compared GSH-depleted with wild-type K562 cells. Our
findings might indicate that at higher CDDP cytotoxicity
levels the protective potential of GSH is overwhelmed by the
extensive cellular damage caused by CDDP. TSH consists of
GSH and protein-bound sulphydryl groups. Protein-bound
sulphydryl is usually thought to be indicative of the amount
of cellular metallothionein, a group of proteins with a high
cysteine content. Elevated amounts of metallothionein are
found in some cell lines with acquired CDDP resistance (for
review see Andrews and Howell, 1990). But the role of
metallothioneins in the CDDP sensitivity of tumour cells has
been mainly established in cell lines in which metallothionein
has been induced with other heavy metals (for review see
Andrews and Howell, 1990). However, the role of metal-
lothioneins in CDDP resistance seems complex. Recently, it
has been reported that in Chinese hamster ovary cells tran-
sient induction of constitutive metallothionein leads to
decreased CDDP sensitivity (Koropatnick and Pearson,
1993). In contrast, in the same cell line, overexpression of a
transfected mouse metallothionein gene leads to an increased
CDDP sensitivity (Koropatnick and Pearson, 1993). In the
present model higher amounts of TSH were found in the
germ cell tumour cell lines than in the colon carcinoma lines.
In view of the data of Koropatnick and Pearson (1993), this
should imply that the metallothioneins in the present model
behaved like the transfected mouse metallothioneins and not
like those induced by heavy metal incubation of the cells.
Another possible explanation might be the finding that rat
testicular metal-binding proteins were not, in contrast to the
metal-binding proteins in other tissues, metallothioneins
(Waalkes and Perantoni, 1986). Compared with metallo-
thionein, these testicular proteins had a similar molecular
weight but a different amino acid composition; most striking
was the small amount of cysteine residues present. Analo-
gously, it could be that the sulphydryl-containing proteins in
germ cell tumours were different from those in colon car-
cinoma. Based on the inverse correlation between TSH and
ICm, it could even be speculated that, if these proteins do
bind Pt, a toxic complex might be formed in the germ cell
tumour cell lines. Increased GST activity has been found in
several cell lines with acquired CDDP resistance (for review
see Andrews and Howell, 1990). However, in our study no
direct correlation of GST activity with CDDP sensitivity was
observed. In the analysis of variance, GST activity in com-
bination with GSH level and Pt bound to DNA showed a
correlation with CDDP sensitivity at IC50. This is compatible
with a role of GST in cellular detoxification in these cell
lines. There was no difference between both groups of cell
lines with respect to GST activity of amount of GSTrc.
However, the GST activity in colon carcinomas is generally
reported to be increased (Moscow et al., 1989; Peters et al.,
1992), while in germ cell tumours GST activity is decreased
compared with normal adjacent tissue (Strohmeyer et al.,
1992). Probably normal germ cells depend on a high GST
level for cellular detoxification and, therefore, the lower GST
in the germ cell tumour cell lines may be one of the causes of
their CDDP sensitivity.
Topo I activity was similar in all cell lines. Giaccone et al.
(1992) also described only small differences in topo I RNA
expression in in vitro untreated lung carcinoma cell lines,
while in these lines CDDP sensitivity varied as well as sen-
sitivity to drugs for which topo I is the target. Also, in an
ovarian carcinoma cell line with in vitro acquired CDDP
resistance, cross-resistance for a topo I-directed drug in the
absence of a difference in topo I levels was found (Niimi et
al., 1992). So, although it cannot be stated on the basis of
these results that topo I does not play a role in CDDP
resistance, its activity is not a predictive factor for CDDP
sensitivity in vitro. Fry et al. (1991) found a higher topo II
expression in germ cell tumour cell lines than in bladder
tumour cell lines, and in a panel of lung cancer cell lines high
topo II RNA expression correlated with sensitivity for multi-
ple drugs, including CDDP (Giaccone et al., 1992). In cell
lines with acquired CDDP resistance decreased (Yang and
Douple, 1991) as well as increased (De Jong et al., 1991)
topo II activities have been found compared with their sen-
sitive parental lines. In our cell lines we found no correlation
between topo II activity and CDDP sensitivity and no
difference between the two groups of tumour types. The high
topo II activity in 833 KE was in agreement with the high
levels in this cell line described by Fry et al. (1991). But a
high topo II level was not found in the two other germ cell
tumour cell lines. Combined with the varying results that
have been found in acquired CDDP resistance, these data
exclude a direct, common role for topo II in CDDP resis-
tance.
Decrease of cellular Pt uptake in cells with in vitro
acquired resistance is a frequent mechanism of resistance (for
review see Gately and Howell, 1993), and the amount of Pt
bound to DNA in tumour cells in vitro is often correlated
with CDDP sensitivity (Sherman and Lippard, 1987). In a
report by Bedford et al. (1988), accumulation of Pt in two
germ cell tumour and one bladder tumour cell line correlated
with CDDP sensitivity. The amount of initial DNA platina-
tion after 1 h incubation with CDDP was not in agreement
with the CDDP sensitivity of these lines. However, the
amount of Pt bound to DNA after 1 h incubation with
688Cispladinsensitivity ingrm cell and colon cancercell lines
MWJ Sark etal M
689
CDDP followed by 24 h culture offered a good correlation
(Bedford et al., 1988). In contrast, Hill et al. (1994) found the
lowest DNA platination in the most sensitive lines and the
highest in the most insensitive lines, using a panel of four
germ cell tumour cell lines and an incubation and post-
incubation scheme according to Bedford et al. (1988). In our
model cellular Pt uptake did not correlate with sensitivity.
The germ cell tumour cell line Scha, for example, had a high
cellular Pt level, while the most sensitive germ cell tumour
cell line, Tera, had a low cellular Pt content. Pt bound to
DNA did not correlate with sensitivity unless combined with
parameters of cellular detoxification. This is surprising as Pt
binding to DNA is usually considered to be the mechanism
of toxicity of CDDP. Correlation with Pt bound to DNA at
t= 24 h was found in the group of germ cell tumour cell
lines, but not in the group of colon carcinoma cell lines. An
increase in Pt-DNA levels during the 24-h post-incubation
period was also found in two of the germ cell tumour cell
lines described by Hill et al. (1994). As that study used an
immunochemical technique whereas the present study used
AAS to measure Pt-DNA, it is unlikely that this increase is
due to an artifact of the technique used. The fact that we
also found increases in Pt bound to DNA in one colon
carcinoma and no repair in another seemed contrary to the
results reported by Bedford et al. (1988). In that study the
resistant cell line was incubated with a concentration of
CDDP close to its own ICm. In our study the resistant cell
lines were incubated with CDDP concentrations exceeding
their IC50 by 4- to 8-fold. In these circumstances a lack of
repair capacity is also found in the colon carcinoma cell lines.
This suggested that the lack of repair capacity described for
germ cell tumour cell lines (Bedford et al., 1988; Kelland et
al., 1992; Hill et al., 1994) might be at least partly due to the
high incubation concentrations relative to their IC50 values in
the studies described, and not only to a unique phenomenon
in germ cell tumour cell lines.
Analysis of variance was used to correlate combinations of
parameters with sensitivity. It showed a good correlation
between IC50, the parameter normally used to indicate drug
sensitivity, and Pt bound to DNA in combination with GSH
and GST activity. However, at other cytotoxicity levels (IC1o
and IC90) also, combined correlations with other parameters
such as topo II activity, cellular Pt content and TSH were
found. The diversity of correlations might indicate that in
these cell lines different mechanisms may be important at
different levels of sensitivity, although since only a few cell
lines were analysed the results can only be used as a
guideline. The fact that at all cytotoxicity levels one or more
components of the detoxifying system are involved is a
strong indication for the relevance of this system in intrinsic
tumour cell CDDP sensitivity. On the other hand, the con-
tribution of a certain parameter in the various cell lines
might vary widely. For instance, in the germ cell tumour cell
line Scha, the GSH level was similar to that in the colon
carcinoma cell line SW 948. But the high Pt accumulation in
Scha seemed to overwhelm its GSH pool, leading to a higher
Pt-DNA binding (t= 0) in Scha than in SW 948 after
incubation with the same CDDP concentration. The colon
carcinoma cell line Caco-2 exhibited a high degree of Pt
accumulation but a low level of Pt-DNA binding. This
might be caused by a high efficacy of its detoxifying system,
as GSH levels and GST activity were the highest in this cell
line.
Based on our model of unselected cell lines it can be
concluded that multiple parameters must be analysed to ex-
plain CDDP resistance in vitro. However, other parameters
that we did not include in this study (for review see Kelland,
1994) might explain the sensitivity of germ cell tumour and
the insensitivity of colon carcinoma cell lines. Thus the sen-
sitivity of germ cell tumours to a range of drugs inducing
DNA damage (Masters et al., 1993) and the possible role of
DNA damage recognition proteins (McLaughlin et al., 1993)
are intriguing.
In conclusion, the study described here did not reveal a
cause of the unique sensitivity of germ cell tumours, but the
unexpected relation between ICso and TSH should be studied
further.
Abbrevations: AAS, atomic absorption spectrophotometry; CDDP,
cisplatin, cis-diamminedichloroplatinum(II); CDNB, 1-chloro-2,4-
dinitrobenzene; FCS, fetal calf serum; GSH, glutathione; GST,
glutathione S-transferase; ICIO, drug concentration inhibiting survival
by 10%; IC"0, drug concentration inhibiting survival by 50%; IC90,
drug concentration inhibiting survival by 90%; PBS, phosphate-
buffered saline (0.14M sodium chloride, 2.7 mm potassium chloride,
6.4mM disodium hydrogen phosphate, 1.5 mm potassium dihydrogen
phosphate, pH 7.4); Pt, platinum; topo, DNA topoisomerase; TSH,
total sulphydryl content.
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